Key facts
- This page summarizes Merdad Parsey's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Dec 2024, 19:24.
Merdad Parsey - 10 Dec 2024 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- GILD
- Reported as of
- 10 Dec 2024
- Net transaction value
- -$163,534
- SEC form
- 4
- Accepted by SEC
- 11 Dec 2024, 19:24:27 UTC
- Prior SEC filing
- 29 Nov 2024
- Next SEC filing
- 13 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Edward S. Son by Power of Attorney for Merdad Parsey
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Merdad Parsey filed Form 4 for GILEAD SCIENCES, INC. (GILD) on 11 Dec 2024.
Change
- Previous filing in this sequence was filed on 29 Nov 2024.
- Current net transaction value: -$163,534.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GILD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,820
- Change %
- +4.7%
- Price
- Shares after
- 84,621
- Date
- 10 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
GILD
transaction
Common Stock
Tax liability
- Transaction value
- $163,534
- Shares
- -1,771
- Change %
- -2.1%
- Price
- $92.34
- Shares after
- 82,850
- Date
- 10 Dec 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GILD
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- -3,820
- Change %
- -9.4%
- Price
- Shares after
- 36,753
- Date
- 10 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,820
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
Footnote F2
The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.